September 29, 2011
EU invests €30 million to boost vaccine researchVienna (Austria) 29 September 2011, Intercell AG is pleased to announce that on 1 October 2011 the collaborative research program – Advanced Immunization Technologies (ADITEC) – will start in order to accelerate the development of novel and powerful immunization technologies for the next generation of human vaccines. ADITEC is co-funded with €30 million by the European Commission to establish a robust platform for innovation in this key strategic area with a high socio-economic impact. Scientists from 42 research partners in 13 countries will collaborate in this new program.
“We are at a unique point in vaccine history,” says Rino Rappuoli, coordinator of ADITEC and president of the Sclavo Vaccines Association (SVA) which is based in Siena /Italy . “Progress in science and technology makes it possible to achieve what was previously deemed impossible. New technologies are opening the door to fight those diseases for which new vaccines could not be developed so far. However, a single laboratory cannot tackle modern vaccine science in isolation. Therefore we have set up this project consortium with scientists from 42 research bodies to collaboratively produce the knowledge necessary for the development of novel and powerful immunization technologies for the next generation of human vaccines.”
ADITEC comprises a team of competitive European universities and research institutions next to top US groups on systems biology and adjuvants. The project is reinforced by a number of key European industries, both big pharmaceutical and smaller biotechnology companies -these corporations are focusing on specific innovative technologies that now allow making better and safer vaccines-. In addition, the World Health Organization is supporting the project as a senior partner, ensuring that cross-cutting global health aspects are duly considered.
This research program covers a wide range of crucial aspects of vaccination; from basic research or new technologies to clinical trials and public health. The high impact project will therefore lead to: improved potency and safety of vaccines and their components, novel routes and devices of administration, optimized vaccination strategies, optimized formulations and vaccination methods for different age groups, better insight in the effects of gender, chronic diseases and genetic variation on vaccination and widespread knowledge about the available new technologies.
Start date: 01/10/2011
End date: 30/09/2016Project cost: €41 millionEU contribution: €30 millioninfo@associazionesclavo.org, Tel: + 39-0577-233307Sclavo Vaccines Association, Italy
Statens Serum Institut, DenmarkSt George University of London, United KingdomMax Planck Institute for Infection Biology, GermanyUniversity of Siena, ItalyInstitute Pasteur, FranceUniversity of Oxford, United KingdomUniversity of Geneva, SwitzerlandNovartis Vaccines and Diagnostics s.r.l., ItalyIntercell AG, AustriaUniversity of Goteborg, SwedenLeiden University and Medical Centre, The NetherlandsEmory University Atlanta, USA Tuberculosis Vaccine Initiative, The NetherlandsInstitute for Biomedical Aging Research, AustriaInfectious Disease Research Institute Seattle, USAUtrecht University, The Netherlands Fondazione Humanitas per la Ricerca, ItalyFondazione per l’Istituto di Ricerca in Biomedicina, SwitzerlandIstituto Superiore di Sanità, ItalyKings College London, United KingdomWorld Health Organization, SwitzerlandFrench Atomic Energy, FranceInstitut de Biologie et Chimie des Protéines, FranceErasmus Medical Center, The Netherlands ALTA s.r.l.u, ItalyMedicine in need, FrancedeCODE Genetics, IcelandOkairos, ItalySigmoid Pharma, IrelandVaccibody, NorwayPevion Biotech, SwitzerlandDuotol AB, SwedenCrossbeta Biosciences, The Netherlands Microbiotecsrl, ItalyArenaVax, SwitzerlandXbrane Bioscience AB, SwedenBioneedle Group, The Netherlands Novartis Vaccines Institute for Global Health s.r.l, ItalyNational Institute for Biological Standards and Control, United KingdomSeattle Biomedical Research Institute, USA Imperial College London, UK